# Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

> **NCT04191148** · PHASE1 · COMPLETED · sponsor: **Locus Biosciences** · enrollment: 36 (actual)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** LBP-EC01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04191148
- **Lead sponsor:** Locus Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-30
- **Primary completion:** 2020-11-19
- **Final completion:** 2020-11-19
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191148, "Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04191148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*